Dear Senator Cruz,
I am writing you regarding the Lower Drug Costs Through Competition Act. This is a bill proposed by Representatives Gus Bilirakis (R-FL) and Kurt Schrader (D-OR) introduced Jan 29th, 2017, and assigned to the House Committee on Energy and Commerce Health. The House and Senate have not voted on it yet. This bill would speed up generic drug development by promoting competition in efforts to reduce high generic prescription costs. It would expedite review and approval of generic drugs to applications where there is a shortage, or for the generic drugs that have not been introduced to the market by more than one manufacturer, AND for which approval has not already been granted.
In my research on this matter, I learned that the “FDA generated its highest number of approvals of generics in 2017, with more than 800 generic drug approvals, including full and tentative ones, according to the FDA blog” (Pharmacy Times, 2017). This however is not enough, and more needs to be done to lower medication costs for Americans. Therefore, my position is in support of HR 749: Lower Drug Costs Through Competition Act. I believe that any bill that increases competition among big pharmaceutical companies is a good one as they are far too wealthy and powerful, and need more regulations on them in order to provide the public with affordable medications. Medication manufacturing has become less about health, and more about making millions of dollars. Americans that you represent should not be dying because they cannot afford their medications. You have the power to take a step towards making healthcare more affordable by supporting this bill.
Thank you for your time and consideration in this important matter.